Avant Diagnostics, Inc. (AVDX) Presenting at the S
Post# of 104
Posted On: 02/19/2016 3:16:37 PM
Avant Diagnostics, Inc. (AVDX) Presenting at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference
Earlier today, Avant Diagnostics, Inc. (OTCQB: AVDX) announced that it will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference, which will take place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a presenter, Avant will be provided with a 30-minute time slot with which to present to an audience of investors and industry professionals. The company’s management team is also expected to be available for one-on-one meetings with institutional investors attending the event.
To view a complete list of presenting companies, visit http://steconference.com/presenting-companies
This announcement follows last month’s news that Avant has entered into a letter of intent to merge with Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS). The proposed merger is expected to create opportunities for the combined company to progress the development of highly valuable diagnostic assets – including Avant’s OvaDx® large panel biomarker test for use in monitoring women at a heightened risk for ovarian cancer, as well as Amarantus Diagnostics’ MSPrecise® diagnostic assay for multiple sclerosis and LymPro Test® flow cytometry assay for Alzheimer’s disease.
“After exploring numerous avenues for implementing Avant’s OvaDx® development and commercialization strategy, it is clear that combining Avant’s and Amarantus’ diagnostic assets and core competencies forms a platform that provides maximum value to our collective shareholders,” Gregg Linn, president and chief executive officer of Avant, stated in a recent news release. “The collective diagnostic assets will create a truly unique opportunity to implement our respective missions of saving and enhancing lives through early detection of disease in oncology and neurology.”
SeeThruEquity, a leading independent equity research and corporate access firm, released a report studying the potential effects of the Avant merger last month. Among the highlights, the SeeThruEquity report inferred that, when completed, the proposed merger “will allow them to progress at a much faster pace and to develop valuable diagnostic assets in areas of oncology and neurology.” The report went on to note that the combined assets of Avant and Amarantus Diagnostics “have the potential to improve the practice of medicine by providing new proprietary diagnosis and monitoring tools for oncologists and neurologists.”
If approved for commercialization, OvaDX, in particular, is expected to offer a clear improvement to the current diagnostic standard by substantially improving the accuracy of diagnosis and allowing for a more effective therapeutic triaging and intervention strategy. It’s estimated that the market opportunity for OvaDx is $50 million annually as a diagnostic test for ovarian cancer, and this opportunity would expand to over $2 billion annually if it were to be approved as a generalized screening and/or monitoring tool.
For more information, visit the company website at www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Earlier today, Avant Diagnostics, Inc. (OTCQB: AVDX) announced that it will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference, which will take place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a presenter, Avant will be provided with a 30-minute time slot with which to present to an audience of investors and industry professionals. The company’s management team is also expected to be available for one-on-one meetings with institutional investors attending the event.
To view a complete list of presenting companies, visit http://steconference.com/presenting-companies
This announcement follows last month’s news that Avant has entered into a letter of intent to merge with Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS). The proposed merger is expected to create opportunities for the combined company to progress the development of highly valuable diagnostic assets – including Avant’s OvaDx® large panel biomarker test for use in monitoring women at a heightened risk for ovarian cancer, as well as Amarantus Diagnostics’ MSPrecise® diagnostic assay for multiple sclerosis and LymPro Test® flow cytometry assay for Alzheimer’s disease.
“After exploring numerous avenues for implementing Avant’s OvaDx® development and commercialization strategy, it is clear that combining Avant’s and Amarantus’ diagnostic assets and core competencies forms a platform that provides maximum value to our collective shareholders,” Gregg Linn, president and chief executive officer of Avant, stated in a recent news release. “The collective diagnostic assets will create a truly unique opportunity to implement our respective missions of saving and enhancing lives through early detection of disease in oncology and neurology.”
SeeThruEquity, a leading independent equity research and corporate access firm, released a report studying the potential effects of the Avant merger last month. Among the highlights, the SeeThruEquity report inferred that, when completed, the proposed merger “will allow them to progress at a much faster pace and to develop valuable diagnostic assets in areas of oncology and neurology.” The report went on to note that the combined assets of Avant and Amarantus Diagnostics “have the potential to improve the practice of medicine by providing new proprietary diagnosis and monitoring tools for oncologists and neurologists.”
If approved for commercialization, OvaDX, in particular, is expected to offer a clear improvement to the current diagnostic standard by substantially improving the accuracy of diagnosis and allowing for a more effective therapeutic triaging and intervention strategy. It’s estimated that the market opportunity for OvaDx is $50 million annually as a diagnostic test for ovarian cancer, and this opportunity would expand to over $2 billion annually if it were to be approved as a generalized screening and/or monitoring tool.
For more information, visit the company website at www.avantdiagnostics.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)